Unraveling the Genetic Heterogeneity of Acute Lymphoblastic Leukemia Based on NGS Applications.

Simple Summary: Acute lymphoblastic leukemia (ALL) remains the most frequent cancer among pediatric patients and accounts for about a quarter of adult leukemias. Understanding the biological processes through which leukemogenesis originates and is maintained remains a challenge. Advances in different omics technologies have broadened our understanding and have enabled better diagnosis and management of patients by enabling the identification of biomarkers with prognostic impact, including genomic, transcriptomic, and epigenomic markers. Therefore, the aim of this review is to compare, summarize, and highlight some of the recent findings in acute lymphoblastic leukemia based on NGS applications. Acute lymphoblastic leukemia (ALL) is a hematological neoplasm characterized by the clonal expansion of abnormal lymphoid precursors in bone marrow, which leads to alterations in the processes of cell differentiation and maturation as a consequence of genetic alterations. The integration of conventional methods, such as cytogenetics and immunophenotyping, and next-generation sequencing (NGS) has led to significant improvements at diagnosis and patient stratification; this has also allowed the discovery of several novel molecular entities with specific genetic variants that may drive the processes of leukemogenesis. Nevertheless, the understanding of the process of leukemogenesis remains a challenge since this disease persists as the most frequent cancer in children; it accounts for approximately one-quarter of adult acute leukemias, and the patient management may take into consideration the high intra- and inter-tumor heterogeneity and the relapse risk due to the various molecular events that can occur during clonal evolution. Some germline variants have been identified as risk factors or have been found to be related to the response to treatment. Therefore, better knowledge of the genetic alterations in B-ALL will have a prognostic impact from the perspective of personalized medicine. This review aims to compare, synthesize, and highlight recent findings concerning ALL obtained through NGS that have led to a better understanding of new molecular subtypes based on immunophenotypic characteristics, mutational profiles, and expression profiles. [ABSTRACT FROM AUTHOR]